PERTH, Australia – As Australia gets ready for its national election on May 18, the life sciences industry is putting pressure on both political parties to reform the country's research and development tax incentive (RDTI).

PERTH, Australia – Australian regenerative medicine company Orthocell Ltd. saw its stock shoot up 350% on Australia's Securities Exchange (ASX:OCC) last week following interim results of its nerve regeneration trial that saw patients regain sensation and muscle function following Celgro nerve regeneration treatment.

PERTH, Australia – As Australia gets ready for its national election on May 18, the life sciences industry is putting pressure on both political parties to reform the country's research and development tax incentive (RDTI).

PERTH, Australia – Australia's largest venture capital firm, Brandon Capital Partners, has raised AU$210 million (US$147 million) for a new medical research fund that will invest in early stage discoveries linked to Medical Research Commercialization Fund (MRCF) members, a network of more than 50 medical research institutes and hospitals across Australia and New Zealand.

PERTH, Australia – Drug safety advisories around the globe are often inconsistent, and Australia's Therapeutic Goods Administration (TGA) is one of the most inconsistent compared to its peers, according to a review of drug regulators in Australia, Canada, the U.K. and the U.S. over the last decade.

PERTH, Australia – Australia's largest venture capital firm, Brandon Capital Partners, has raised AU$210 million (US$147 million) for a new medical research fund that will invest in early stage discoveries linked to Medical Research Commercialization Fund (MRCF) members, a network of more than 50 medical research institutes and hospitals across Australia and New Zealand.